Phenotypic and Genotypic Adaptations in Pseudomonas aeruginosa Biofilms following Long-Term Exposure to an Alginate Oligomer Therapy
Juliette L. Oakley,
Rebecca Weiser,
Lydia C. Powell,
Julian Forton,
Eshwar Mahenthiralingam,
Philip D. Rye,
Katja E. Hill,
David W. Thomas,
Manon F. Pritchard
Affiliations
Juliette L. Oakley
Advanced Therapies Group, Oral and Biomedical Sciences, School of Dentistry, College of Biomedical and Life Sciences, Cardiff University, Cardiff, United Kingdom
Rebecca Weiser
Cardiff School of Bioscience, Cardiff University, Cardiff, United Kingdom
Lydia C. Powell
Advanced Therapies Group, Oral and Biomedical Sciences, School of Dentistry, College of Biomedical and Life Sciences, Cardiff University, Cardiff, United Kingdom
Julian Forton
Department of Paediatric Respiratory Medicine/Cystic Fibrosis Unit, Children’s Hospital for Wales, Cardiff, United Kingdom
Advanced Therapies Group, Oral and Biomedical Sciences, School of Dentistry, College of Biomedical and Life Sciences, Cardiff University, Cardiff, United Kingdom
David W. Thomas
Advanced Therapies Group, Oral and Biomedical Sciences, School of Dentistry, College of Biomedical and Life Sciences, Cardiff University, Cardiff, United Kingdom
Advanced Therapies Group, Oral and Biomedical Sciences, School of Dentistry, College of Biomedical and Life Sciences, Cardiff University, Cardiff, United Kingdom
The emergence of multidrug-resistant (MDR) pathogens within biofilms in the cystic fibrosis lung results in increased morbidity. An inhalation therapy derived from alginate, OligoG CF-5/20, is currently in clinical trials for cystic fibrosis patients.
